Clinical trial
A Phase IIIb, Randomized, Double-Blind, Parallel Group Study in Bipolar I Patients to Assess the Efficacy and Safety of SPD417 Administered Once Daily vs Twice Daily in the Treatment of Manic Symptoms
NCT00150553 is registered in ClinicalTrials.gov with Validus Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIIb, Randomized, Double-Blind, Parallel Group Study in Bipolar I Patients to Assess the Efficacy and Safety of SPD417 Administered Once Daily vs Twice Daily in the Treatment of Manic Symptoms
- Lead sponsor
- Validus Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2005
- Completion date
- October 31, 2005
- Enrollment
- 102
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.